Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
Money

NIH awarded Eveliqure Biotechnologies GmbH contract 75N93020C00048 to fund cGMP manufacturing and lot release of the Shigetec vaccine for Phase 2 trials.

Why it’s here: NIH award funding cGMP manufacturing and Phase 2 clinical trials of a vaccine is biotechnology funded by a federal health agency, fitting the Biotechnology area's NIH/biosecurity programs.

Trace across the board

Item

Connected

15 links

About

  • National Institutes of Health
  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

NIH awarded Eveliqure Biotechnologies GmbH contract 75N93020C00048 to fund cGMP manufacturing and lot release of the Shigetec vaccine for Phase 2 trials. — The Wave